ClinicalTrials.gg
RecruitingNCT05608278Updated Mar 7, 2023

Four-day Intensive Treatment Versus Standard Cognitive Behavioral Therapy for Adults With Obsessive-compulsive Disorder

An interventional study of Bergen 4-Day Treatment (B4DT) and Gold standard cognitive behavioral therapy (gold standard CBT) in Obsessive-Compulsive Disorder, sponsored by Karolinska Institutet. Recruiting at 2 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-07.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Nov 2022; still recruiting 4 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet — 3 open to participants now, 3 under way, none of them phase 3. Obsessive-Compulsive Disorder · Karolinska Institutet.

Planned enrollment
3rd of 15
120 · median 83
Started
2022
with 1 other
No phase
13 of 17
3 open now
Registered
15th of 17
by date

Among the 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet, this one is the 3rd largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 13 with no phase, and was the 15th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

3 of the 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Obsessive-Compulsive Disorder by Karolinska Institutet, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare a novel, condensed version of cognitive behavioral therapy (Bergen 4-Day Treatment, B4DT) to the gold standard psychological treatment (gold-standard CBT) for obsessive compulsive disorder (OCD).

The main question it aims to answer is:

  • Is B4DT non-inferior to standard cognitive behavioral therapy (CBT) with regard to OCD symptoms 14 weeks after treatment start?

Adult patients with obsessive compulsive disorder will be randomly assigned to receive either gold standard CBT one to two times per week for 14 weeks, or 4 days of B4DT during one week.

Read the detailed description

Obsessive-compulsive disorder is a persistent and disabling psychiatric disorder. Individual cognitive behavioral therapy (CBT) with exposure and response prevention (ERP) is an effective treatment for OCD and is recommended as a first-line intervention. However, patients need to remain in treatment for several months and even after that, around 50% remain symptomatic despite this lengthy treatment. In response to this, a novel, condensed version of CBT, B4DT, has been developed. B4DT has shown promising results in several uncontrolled trials and one randomized controlled trial with inactive control, however it has yet to be directly compared to gold-standard individual CBT.

This single blind, randomized controlled trial with 120 patients (60 per arm) will compare B4DT to gold standard CBT. The primary outcome is the blind-rater administered Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). The investigators hypothesize that B4DT will be non-inferior to gold standard CBT 14 weeks after treatment start. The non-inferiority margin is set at 4 points on the Y-BOCS.

Secondary outcomes are cost effectiveness, speed of response, response and remission rates, dropout rate, and negative effects. The investigators hypothesise that participants that receive B4DT will improve faster than patients that receive standard CTB, but for the rest of the secondary outcomes, the investigators have no directed hypotheses.

A more detailed preregistration, and all analysis scripts, are available at Open Science Framework (https://osf.io/w5bfp/).

03

Conditions studied

  • Obsessive-Compulsive Disorder

Keywords

  • Cognitive Behavioral Therapy
  • Obsessive-Compulsive Disorder
  • Randomized Controlled Trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age.
  2. Primary diagnosis of OCD according to the 5 (DSM-5).
  3. Clinician-rated Y-BOCS score of ≥ 16
  4. Written .
  5. To be willing and able to attend treatment at any one of the two treatment clinics, regardless of the clinic where the initial assessment took place (the two clinics are located at different locations in Stockholm, about 20 Km apart).
  6. Be fluent in Swedish.

Exclusion criteria

Exclusion Criteria:

  1. Other psychological treatment for OCD planned during trial period.
  2. Completed CBT with ERP for OCD in the last 12 months.
  3. Changes in psychotropic medication within the last 2 months.
  4. Bipolar disorder.
  5. Psychosis.
  6. Alcohol or substance dependence.
  7. Organic brain disorder.
  8. Hoarding disorder or OCD with primary hoarding symptoms.
  9. Suicidal ideation that would warrant close monitoring.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Bergen 4-Day Treatment (B4DT)

    Patients in this arm will receive an intensive treatment delivered mostly in group format. The group sizes will be 3-6 participants with a 1:1 patient to therapist ratio. In the week before the intensive part of the treatment, participants will have two scheduled phone/video calls with a therapist. Day 1 (half-day) of the intensive treatment includes psychoeducation and deciding on exposure tasks. Days 2 and 3 (whole days) focus on individually tailored and therapist-assisted ERP in as many most relevant settings as possible. In the evenings, patients are encouraged to continue with self-guided ERP and may receive therapist support via text messages or phone calls on demand. On day 3, patients can invite relatives to a psychoeducation session. Day 4 (half-day) of the intensive treatment focuses on treatment summary and relapse prevention, as well as planning self-guided ERP for the upcoming 3 weeks. After 16 weeks, participants have individual follow-up sessions without ERP.

    Behavioral: Bergen 4-Day Treatment (B4DT)

  • Active comparator
    Gold standard cognitive behavioral therapy (gold standard CBT)

    Patients will receive 16 sessions of individual CBT for OCD with an emphasis on ERP, delivered over a time period of 14 weeks according to a validated protocol. Sessions will be held twice weekly at a specialist clinic during the first 2 weeks and once a week for the remaining 12 weeks. Sessions 1-2 contain psychoeducation about OCD and CBT, goal setting, and planning of ERP exercises. Sessions 3-14 include therapist-guided ERP (at the clinic, in the patients' homes or elsewhere as needed) with planned self-practice ERP between sessions. Sessions 15-16 contain a summary of the treatment and lessons learned, as well as relapse prevention and planning of continued self-practice ERP.

    Behavioral: Gold standard cognitive behavioral therapy (gold standard CBT)

Interventions

  • BehavioralBergen 4-Day Treatment (B4DT)

    Novel CBT treatment

  • BehavioralGold standard cognitive behavioral therapy (gold standard CBT)

    Gold standard CBT treatment

06

What researchers measure

Primary outcomes

  1. Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), clinician-administered

    Clinician administered scale that measures the severity of obsessions and compulsions. Ten questions, with scores ranging from 0 to 4 (most severe), address time, interference, distress, resistance and control over obsessions and compulsions (total score range from 0 to 40).

    Time frame: Change from baseline to 14 weeks after treatment start. Additional measures at week 4 and 7, and at the 7- and 16-month follow-up

Secondary outcomes

  1. Clinical Global Impression - Severity (CGI-S)

    Used to assess rates of response and remission. The Clinical Global Impression - Severity (CGI-S) and Clinical Global Impression - Improvement (CGI-I) Scales will be used to assess overall clinical severity and consequent treatment response (scores of "very much improved" (1) or "much improved" (2) will define treatment response according to previous trials in tic disorders.

    Time frame: 14 weeks after treatment start. Additional measures at week 4 and 7, and at the 7- and 16-month follow-up

  2. Clinical Global Impression - Improvement (CGI-I)

    Used to assess rates of response and remission. The Clinical Global Impression - Severity (CGI-S) and Clinical Global Impression - Improvement (CGI-I) Scales will be used to assess overall clinical severity and consequent treatment response (scores of "very much improved" (1) or "much improved" (2) will define treatment response according to previous trials in tic disorders.

    Time frame: 14 weeks after treatment start. Additional measures at week 4 and 7, and at the 7- and 16-month follow-up

  3. Dropout rate in both arms

    A dropout will be defined as a patient in the B4DT arm that participates in less than 1.5 full days at the clinic, or a patient in the gold standard CBT arm that participates in less than 8 CBT sessions.

    Time frame: Gold standard CBT: week 15. B4DT: week 3.

  4. Treatment Inventory of Costs in Psychiatric Patients (TIC-P)

    Self-rated questionnaire on healthcare utilization and productivity losses in patients with a psychiatric disorder. The TIC-P questionnaire measures costs in two dimensions: use of health resources and loss of productivity. Lower cost is better.

    Time frame: Pre-treatment, at week 15, and at the 7- and 16-month follow-ups

  5. Negative Effects Questionnaire (NEQ)

    Self-rated questionnaire on negative effects. It contains 32 items that are scored on a five point Likert-scale (0-4) and differentiates between negative effects that are attributed to treatment and those possibly caused by other circumstances. The total score of the NEQ ranges from 0 to 80 points, a higher score reflects more negative effects.

    Time frame: 14 weeks after treatment start. Additional measures at the 7- and 16-month follow-ups

  6. Assessing Quality of Life 6 Dimensions (AQoL-6D)

    Used to assess cost-effectiveness. 20 questions that assess different aspects of quality of life. The AQoL provides a utility score that ranges from 1.00 (full health) to 0.00 (death-equivalent health states) to -0.04 (health states worse than death).

    Time frame: Change from baseline to 14 weeks after treatment start. Additional measures at the 7- and 16-month follow-ups

Other outcomes

  1. Patient Exposure/Response Prevention Adherence Scale (PEAS)

    Measures the patient's between-session adherence to the therapist's exposure and response prevention instructions. The scale has three subscales: exposure assignments attempted, the quality of exposure assignments attempted, and the percentage of rituals resisted between session. Each subscale ranges from 0 to 100%, high scores represent better adherence.

    Time frame: Gold standard CBT: week 4, 7, and 15. B4DT: week 3.

  2. Yale-Brown Obsessive Compulsive Scale-Self-Rated (Y-BOCS-SR)

    Self rated version of the primary outcome that measures severity of obsessions and compulsions. It consists of 10 items rated on a 5-point Likert scale (0 to 4) with higher scores denoting greater symptom severity.

    Time frame: Pre-treatment, at week 15, and at the 7- and 16-month follow-ups

  3. Montgomery-Åsberg Depression Rating Scale-Self-Rated (MADRS-S)

    Measures symptom severity of depression. MADRS is a 9-item depressive symptoms scale where the symptoms are assessed on a 7-point likert scale from no symtoms to very high severity. The total score ranges from 0 to 54 with higher score indicating more severe problems.

    Time frame: Pre-treatment, at week 15, and at the 7- and 16-month follow-ups

  4. Work and Social Adjustment Scale (WSAS)

    Measures impairment in functioning. Scores range from 0-40, with lower scores representing better functioning.

    Time frame: Pre-treatment, at week 15, and at the 7- and 16-month follow-ups

  5. Credibility/Expectancy Questionnaire (CEQ)

    Measures treatment expectancy and rationale credibility. The CEQ is a 5-item measure of the treatment's credibility and the patients' expectations. The patients assess each domain on a 11-point likert scale (scored 0-10), with a total score ranging between 0-50 where higher score indicates higher credibility and higher expectations.

    Time frame: Week 2

  6. Working Alliance Inventory-Short Form Revised (WAI-SR)

    Measures the therapeutic alliance in therapy. The WAI-SR is a 12-item measure of the patient's experience of their working alliance with the therapist. The patients assess each item on a 7-point likert scale (scored 0-6), with a total score ranging between 0-72 where higher score indicates higher better working alliance according to the patient.

    Time frame: Week 2

  7. Obsessive-Compulsive Inventory-Revised (OCI-R)

    Self-rating scale that measures the severity and type of symptoms of OCD. The Obsessive-Compulsive Inventory-Revised (OCI-R) has 18 items. Each item is scored on a 5 point scale from 0 to 4. Total score ranges from 0 to 72, higher scores represent more severe OCD.

    Time frame: Pre-treatment, at week 15, and at the 7- and 16-month follow-ups

07

Study locations

2 of 2 sites recruiting
  • Psykiatri Nordväst, Stockholms Läns Sjukvårdsområde (SLSO), Stockholms Läns Landsting
    Stockholm, Sweden
    Recruiting
  • Psykiatri sydväst
    Stockholm, Sweden
    Recruiting
    • Christian Ruck, MD, PHD · ContactChristian.ruck@ki.se · +46(0)70484 33 92
    • Christian Ruck, MD, PhD · Principal investigator
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Raw data will be shared through a searchable database, Swedish national data service (SND), with restricted access. Only meta-data will be shared without restrictions. Researchers that want access to the raw data data will have to submit an additional application an ethical review board.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: The supporting information will become available for everybody on Open Science Framework (https://osf.io/w5bfp/) before inclusion of the first participant. We will not delete anything, potential changes will be transparently reported through time stamped documents. We plan to submit the raw data to SND after completion. We will never delete it.

Access criteria: Approved ethics application.

Data sharing details ↗ · snd.gu.se

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Aug 2024, 21 months after the start.

Of 235 non-industry interventional studies with no phase under Obsessive-Compulsive Disorder, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 63. This study's planned 21 months is below that.

Counting every sponsor, half of 238 studies reached it within 43 months; a quarter within 22 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Nov 8, 2022
StartActual
Nov 17, 2022
Primary completionEst.
Aug 30, 2024
CompletionEst.
Aug 30, 2025
Last update
Mar 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05608278
Collaborators
Helse-Bergen HF
Responsible party
Christian Rück (Professor, Karolinska Institutet) — Principal investigator
First posted
Nov 8, 2022
Start date
Nov 17, 2022
Primary completion
Aug 30, 2024 (estimated)
Completion
Aug 30, 2025 (estimated)
Last update
Mar 7, 2023

Study contacts

Christian Rück, PhD
Contact
christian.ruck@ki.se
+46704843392
Robin Fondberg, PhD
Contact
robin.fondberg@ki.se
+46709850426

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion